At a glance
ClinicalIndex Comparison RecordN/ACompleted· 215 enrolled
Drug / intervention
AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Investigation of Visual Function After Bilateral Implantation of Two Presbyopia-Correcting Trifocal IOLs
In Brief
A clinical study evaluating AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL and AT LISA® tri IOL for Cataracts. Completed, enrolled 215 participants.
Detailed Summary
The purpose of this study is to clinically evaluate the visual performance of two commercially available presbyopia-correcting Trifocal IOLs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataracts
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartApr 2016
Primary CompletionJul 2017
TodayJul 2026
First PostedFeb 25, 2016
Enrollment StartApr 29, 2016
Primary CompletionJul 17, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.4 years ago
Interventions
AcrySof® IQ PanOptix™ Presbyopia-Correcting IOLdevice
Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
AT LISA® tri IOLdevice
Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient